Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Structure Therapeutics Inc. - American Depositary Shares (NQ: GPCR )

37.66 -0.77 (-2.02%)
Streaming Delayed Price Updated: 10:21 AM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 72,852
Open 38.24
Bid (Size) 37.56 (2)
Ask (Size) 37.77 (1)
Prev. Close 38.44
Today's Range 37.55 - 38.78
52wk Range 26.61 - 75.02
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer
From Structure Therapeutics Inc.
Via GlobeNewswire
Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review
The major indexes reclaimed key levels and many leaders flashed buy signals. 
Via Investor's Business Daily

Performance

YTD
-6.75%
-6.75%
1 Month
-6.07%
-6.07%
3 Month
-20.74%
-20.74%
6 Month
+3.25%
+3.25%
1 Year
+5.06%
+5.06%

More News

Read More
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
Via Investor's Business Daily
Peering Into Structure Therapeutics's Recent Short Interest
Via Benzinga
Structure Therapeutics Appoints Angus C. Russell to Board of Directors
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Announces Participation in Upcoming Investor Conferences
From Structure Therapeutics Inc.
Via GlobeNewswire
3 Promising Biotech Stocks for the Long-Term: August 2024
Via InvestorPlace
GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
Structure Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
3 Biotech Stocks That Could Make Your Summer Unforgettable
Via InvestorPlace
Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.
Via The Motley Fool
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
Via Investor's Business Daily
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
Via Benzinga
ASML Reports Q2 Results, Joins Spirit Airlines And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in July 2024
Via InvestorPlace
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
Via MarketBeat
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
Via MarketBeat
Exposures Product Safety
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Via MarketBeat
The 3 Smartest Biotech Stocks to Buy With $5K Right Now
Via InvestorPlace
Could Structure Therapeutics Become the Next Novo Nordisk?
Via The Motley Fool
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
Via Investor's Business Daily
Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?
Via The Motley Fool
Skye Bioscience Pivots To Obesity After Glaucoma Flop; Shares Plummet
Via Investor's Business Daily
Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.